| Name | Title | Contact Details |
|---|
Formerly known as the new center for advanced biological innovation and manufacturing (or “CABIM”), Landmark Bio, PBLLC is a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today`s cutting-edge research into tomorrow`s breakthrough therapies. The cross-sector partnership harnesses world-leading expertise to accelerate fast-emerging and promising science, the challenges of which are daunting for any single institution to tackle alone. Board members include leaders from Harvard University, Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children`s Hospital, Brigham and Women`s Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Massachusetts Life Sciences Center.
Centrillion Biosciences is a leading genomic and bioinformatics solution provider.
With offices in Philadephia and Boston, SwanBio Therapeutics is developing leading-edge therapies to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is borne of curiosity, collaboration, and compassion. Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.
Taiga Biotechnologies is a privately-held developer of novel therapies for complex diseases including cancers, infectious agents such as HIV and influenza, and hematologic conditions.
Based in San Diego, we are led by an experienced team of entrepreneurs with deep roots in this region`s life sciences ecosystem and specific expertise in GPCR drug discovery and development. Escient Pharmaceuticals is supported by top-tier life-sciences investors with a proven track record for identifying and supporting successful, next-generation medicines companies.